If they occur during or after sexual intercourse:
Other side effects:
Very common(may affect more than 1 in 10 people):
Common(may affect up to 1 in 10 people):
Uncommon(may affect up to 1 in 100 people):
Rare(may affect up to 1 in 1,000 people):
During post-marketing experience, rare cases of unstable angina (heart disease) and sudden death have been reported. It is worth noting that most men who experienced these side effects, although not all of them, had heart problems before taking this medicine. It is not possible to determine if these side effects were directly related to sildenafil.
Reporting of side effects
If you experience any type of side effect, consult your doctor, pharmacist, or nurse, even if it is a possible side effect that does not appear in this leaflet. You can also report them directly through theSpanish System for the Pharmacovigilance of Medicines for Human Use:https://www.notificaram.es.By reporting side effects, you can contribute to providing more information on the safety of this medicine.
Keepthis medicationout of the sight and reach of children.
Do not usethis medicationafter the expiration date that appears onthe box and blister packafter CAD/EXP. The expiration date is the last day of the month indicated.
This medication does not require special storage conditions.
Medications should not be disposed of through drains or in the trash. Dispose of packaging and medications you no longer need at the SIGRE collection pointat the pharmacy. If in doubt, ask your pharmacist how to dispose of packaging and medications you no longer need. By doing so, you will help protect the environment.
Sildenafilo Bexal Composition
Product appearance and packaging contents
Blue-green colored tablets, round in shape, slightly speckled, with a cross-score on both faces and the imprint “100” on one face.
Diameter: 12.5 mm.
The tablets are packaged in blisters of polyvinyl chloride-Aclar/Aluminum or PVC/PVDC/Aluminum.
Packaging sizes:
1, 2, 4, 8, 12 tablets.
Only some packaging sizes may be commercially available.
Marketing authorization holder and manufacturer responsible
Marketing authorization holder
Bexal Farmacéutica, S.A.
Centro Empresarial Parque Norte
Edificio Roble
C/ Serrano Galvache, 56
28033 Madrid
Spain
Manufacturer responsible
Lek Pharmaceuticals d.d.
Verovskova, 57
SLO-1526 Ljubljana,
Slovenia
or
Lek S.A.
Domaniewska 50 C
02-672 Warsaw
Poland
or
Salutas Pharma GmbH
Otto-von-Guericke-Allee 1
39179 Barleben
Germany
or
S.C. Sandoz, S.R.L.
Str. Livezeni nr. 7A
RO-540472 Targu Mures
Romania
This medicine is authorized in the member states of the European Economic Area and in the United Kingdom (Northern Ireland) under the following names:
Denmark:Sempavox 100 mg tabletter
Estonia:Sempavox 100 mg tabletid
Greece:Sempavox 100 mg δισκ?α
Netherlands:Sempavox 100 mg, tabletten
Lithuania:Sempavox 100 mg tabletes
Latvia:Sempavox 100 mg tabletes
United Kingdomand in the United Kingdom (Northern Ireland):Sempavox 100 mg Tablets
Last review date of thisleaflet:August 2022
The detailed information of this medicine is available on the website of the Spanish Agency of Medicines and Medical Devices (AEMPS)http://www.aemps.gob.es/
Есть вопросы по этому лекарству или вашим симптомам? Свяжитесь с лицензированным врачом для получения помощи и персонализированного ухода.